Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model

BACKGROUND: CDK4/6 inhibitors such as ribociclib are becoming widely used targeted therapies in hormone-receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) breast cancer. However, cancers can advance due to drug resistance, a problem in which tumor heterogeneity and evo...

Descripción completa

Detalles Bibliográficos
Autores principales: Grolmusz, Vince Kornél, Chen, Jinfeng, Emond, Rena, Cosgrove, Patrick A., Pflieger, Lance, Nath, Aritro, Moos, Philip J., Bild, Andrea H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301982/
https://www.ncbi.nlm.nih.gov/pubmed/32565737
http://dx.doi.org/10.1186/s12935-020-01337-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301982/
https://www.ncbi.nlm.nih.gov/pubmed/32565737
http://dx.doi.org/10.1186/s12935-020-01337-1

Ejemplares similares